Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

被引：0
|
作者：
Walewski, Jan [1 ]
Paszkiewicz-Kozik, Ewa [1 ]
Warszewska, Agnieszka [1 ]
Borsaru, Gabriela [2 ]
Moicean, Andreea [3 ]
Hellmann, Andrzej [4 ]
Mayer, Jiri [5 ,6 ]
Hauns, Bernhard [7 ]
Mais, Anna [7 ]
Henning, Stefan W. [7 ]
Hentsch, Bernd [7 ]
机构：
[1] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Warsaw, Poland
[2] Spitalul Clin Coltea, Bucharest, Romania
[3] Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
[4] Med Univ Gdansk, Gdansk, Poland
[5] Univ Hosp Brno, Dept Internal Med Hematooncol, Brno, Czech Republic
[6] CEITEC Masaryk Univ, Brno, Czech Republic
[7] 4SC AG, Martinsried, Germany
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1149 / 1149
页数：1
相关论文
共 50 条
  • [1] Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Hellmann, Andrzej
    Janikova, Andrea
    Warszewska, Agnieszka
    Mais, Anna
    Ammendola, Astrid
    Herz, Thomas
    Krauss, Babett
    Henning, Stefan W.
    LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 675 - 684
  • [2] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    BLOOD, 2010, 116 (21) : 1159 - 1159
  • [3] INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Walewski, J.
    Paszkiewicz-Kozik, E.
    Borsaru, G.
    Moicean, A.
    Warszewska, A.
    Strobel, K.
    Biggi, A.
    Hauns, B.
    Mais, A.
    Henning, S.
    Hentsch, B.
    HAEMATOLOGICA, 2010, 95 : S27 - S27
  • [4] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [5] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Terui, Yasuhito
    Yamamoto, Kazuhito
    Fukuhara, Noriko
    Choi, Ilseung
    Kuroda, Junya
    Ando, Kiyoshi
    Hattori, Akira
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
  • [6] UPDATED RESULTS OF A PHASE II TRIAL OF BENDAMUSTINE IN RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
    Moskowitz, A. J.
    Hamlin, P.
    Gerecitano, J.
    Horwitz, S.
    Matasar, M.
    Noy, A.
    Palomba, M. L.
    Portlock, C.
    Straus, D.
    Graustein, T.
    Zelenetz, A.
    Moskowitz, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 180 - 181
  • [7] Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
    Stuver, Robert
    Vardhana, Santosha A.
    Ganesan, Nivetha
    Boardman, Alexander P.
    Caron, Philip
    Chang, Tiffany
    David, Kevin A.
    Epstein-Peterson, Zachary D.
    Falchi, Lorenzo
    Ghione, Paola
    Hamlin, Paul A.
    Hernandez-Ilizaliturri, Francisco
    Horwitz, Steven
    Intlekofer, Andrew M.
    Johnson, William T.
    Karmali, Reem
    Lue, Jennifer Kimberly
    Kumar, Anita
    Luttwak, Efrat
    Mahajan, Neena
    Marouf, Amira
    Noy, Ariela
    Owens, Colette
    Palomba, Maria Lia
    Salles, Gilles
    Schoder, Heiko
    Sermer, David
    Seshan, Venkatraman
    Steiner, Raphael E.
    Torka, Pallawi
    Zelenetz, Andrew D.
    von Keudell, Gottfried
    Moskowitz, Alison
    BLOOD, 2024, 144 : 3053 - 3055
  • [8] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [9] AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
    Sasse, Stephanie
    Momotow, Jesko
    Plutschow, Annette
    Huttmann, Andreas
    Basara, Nadezda
    Koenecke, Christian
    Martin, Sonja
    Bentz, Martin
    Grosse-Thie, Christina
    Thorspecken, Sven
    de Wit, Maike
    Kobe, Carsten
    Dietlein, Markus
    von Tresckow, Bastian
    Fuchs, Michael
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2020, 136
  • [10] AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial
    Momotow, J.
    Sasse, S.
    Pluetschow, A.
    Huettmann, A.
    Basara, N.
    Koenecke, C.
    Martin, S.
    Bentz, M.
    Grosse-Thie, C.
    Thorspecken, S.
    de Wit, M.
    Kobe, C.
    Dietlein, M.
    von Tresckow, B.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 89
12345